Eli Lilly and Company (NYSE:LLY) Shares Sold by AlphaMark Advisors LLC

AlphaMark Advisors LLC lessened its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 20.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 638 shares of the company’s stock after selling 160 shares during the quarter. AlphaMark Advisors LLC’s holdings in Eli Lilly and Company were worth $565,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of LLY. Lynx Investment Advisory bought a new position in Eli Lilly and Company during the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC bought a new position in Eli Lilly and Company during the second quarter worth $36,000. Redmont Wealth Advisors LLC bought a new position in Eli Lilly and Company during the first quarter worth $40,000. Morton Brown Family Wealth LLC boosted its holdings in Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after purchasing an additional 15 shares during the period. Finally, Cedar Mountain Advisors LLC increased its stake in Eli Lilly and Company by 53.3% during the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after purchasing an additional 16 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on LLY shares. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Berenberg Bank lifted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,025.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Citigroup initiated coverage on Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 16th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $986.00.

Check Out Our Latest Stock Analysis on LLY

Eli Lilly and Company Stock Up 0.1 %

Shares of LLY stock opened at $917.18 on Friday. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The business’s fifty day moving average is $920.70 and its 200-day moving average is $856.27. The stock has a market cap of $871.69 billion, a PE ratio of 135.08, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Equities analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

• Five stocks we like better than Eli Lilly and Company
• Investing in Commodities: What Are They? How to Invest in Them
• Insider Selling is not a Signal to Start Selling Gartner Stock
• Buy P&G Now, Before It Sets A New All-Time High
• Taiwan Semiconductor Soars on Earnings With More Room to Run
• What is a Bond Market Holiday? How to Invest and Trade
• Is Lucid Group Nearing the Bottom? What Investors Should Know

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).